Peregrine Pharmaceuticals (NASDAQ: PPHM) reported late on Tuesday fiscal third quarter results which showed losses were less-than-expected as its revenue jumped more than twofold while lower research and development related costs bolstered the bottom line. The Company is now pinning hopes on its lung cancer treatment drug bavituximab whose development came to a halt after questions were raised regarding its efficacy.
Continue reading Peregrine Pharmaceuticals Reports Narrower Q3 Loss (PPHM)